Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Blue Earth Announces $4 Million Registered Direct Offering
-
WaferGen Bio-Systems (WGBS) Prices $15M Offering of Common Stock and Warrants
-
WaferGen Bio-systems Announces Pricing of $15 Million Underwritten Offering
-
ORBCOMM (ORBC) Second Batch of OG2 Closer to Launch, Chardan Capital Markets Says
-
Immune Pharmaceuticals (IMNP) PT Raised to $6.50 at Chardan Capital Markets
-
Discontinuation of Evacetrapib Study Could Provide Modest Boost to Esperion's (ESPR) ETC-1002
-
Pre-Open Stock Movers 10/08: (JMG) (BMR) (EMC) Higher; (CSII) (ORIG) (SHAK) Lower (more...)
-
After-Hours Stock Movers 10/07: (NVLS) (LL) (LBIO) Higher; (CSII) (DB) (EXFO) Lower (more...)
-
Lion Biotechnologies (LBIO) PT Lifted 33% at Chardan Capital Markets to $20
-
PlacementTracker Publishes Third Quarter 2015 PIPE Market League Tables
-
Chardan Capital Says to Buy Spark Therapeutics (ONCE) Peers Following SPK-RPE65 Results (AAVL) (VBLT)
-
Notable Analyst Rating Changes 10/5: (TWTR) (FOLD) (JNPR) Upgraded; (SNI) (LRCX) (FEYE) Downgraded
-
Pre-Open Stock Movers 10/05: (ONCE) (FOLD) (TWTR) Higher; (APP) (FEYE) (VRX) Lower (more...)
-
Chardan Capital Markets Upgrades Amicus Therapeutics (FOLD) to Buy
-
Notable Analyst Rating Changes 9/30: (RF) (CP) (ESPR) Upgraded; (GPS) (GPC) (ITC) Downgraded
-
Pre-Open Stock Movers 09/30: (EZCH) (RENT) (WDC) Higher; (CUDA) (PLNT) (VRNT) Lower (more...)
-
UPDATE: Chardan Upgrades Esperion (ESPR) to Neutral But Maintains Negative Bias
-
Chardan Capital Cuts PT on Esperion Therapeutics (ESPR) to $29; EOP2 Minutes Worse than Expected
-
Chardan Capital Affirms VBL Therapeutics (VBLT) at 'Buy' Following Strong VB-111 Combo Phase 2 Data
-
Chardan Capital Assumes Vuzix Corp. (VUZI) at Buy
-
Axovant Sciences (AXON) Defended at RBC Capital
-
Signal Genetics (SGNL) Signs Second MSA with for MyPRS; Success Could Lead to Larger Phase 3s
-
REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Unusual 11 Mid-Day Movers 9/22: (WPCS) (VBLT) (CANF) Higher; (WGBS) (OPHC) (TANH) Lower
-
Notable Analyst Rating Changes 9/22: (PYPL) (TSL) (ALL) Upgraded; (NTAP) (ABB) (ALSN) Downgraded
-
Pre-Open Stock Movers 09/22: (AMPE) (VBLT) (WFT) Higher; (FCX) (MRD) (HZNP) Lower (more...)
-
After Hours Stocks Movers 09/21: (VBLT) (TRXC) (CORE) Higher; (THO) (MRD) (NMFC) (more...)
-
Chardan Capital Markets Starts Vascular Biogenics Ltd (VBLT) at Buy, PT $25
-
REGENXBIO (RGNX) IPO Opens Up 38%
-
REGENXBIO (RGNX) IPO Prices In-Line at $22
-
REGENXBIO Announces Pricing of Initial Public Offering
-
REGENXBIO Announces Pricing of Initial Public Offering
-
Unusual 11 Mid-Day Movers 9/16: (ITCI) (ADEP) (XNCR) Higher; (NR) (FOLD) (SPCB) LOwer
-
Notable Analyst Rating Changes 9/16: (CST) (YNDX) (ORCL) Upgraded; (HST) (FOLD) (MRK) Downgraded
-
Chardan Capital Markets Downgrades Amicus Therapeutics (FOLD) to Neutral
-
La Jolla Pharmaceutical (LJPC) Closes 2.9M Common Stock Offering
-
La Jolla Pharmaceutical Company Closes Offering of Common Stock
-
Chardan Capital Positive on Globalstar (GSAT) Following FCC Ex Parte Filing on TLPS Demo
-
Chardan Capital Markets, LLC. Announces Hiring of Michael E. Marrus to The Special Equities Group
-
La Jolla Pharmaceutical (LJPC) Prices 2.55M Common Stock Offering at $38/Share
-
La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
-
Notable 52-Week Highs and Lows 9/8: (JBLU) (NAVB) (LJPC) High; (GPRO) (YGE) (VNCE) Low
-
Unusual 11 Mid-Day Movers 9/8: (CAPN) (TE) (LJPC) Higher; (ACI) (YGE) (NOR) Lower
-
REGENXBIO (RGNX) Sees IPO Price of $17 - $19/Share
-
Chardan Capital Markets Starts Nanosphere (NSPH) at Buy
-
Chardan Capital Boosts PT on La Jolla Pharma (LJPC) to $80 Following CEO Meeting
-
Amicus (FOLD) Worth Up to $50/Sh in a Takeover, Chardan Says; Scioderm Deal Terms Suggest Future Sale
-
Notable Analyst Rating Changes 8/31: (QLGC) (TWTR) (MS) Upgraded; (RGS) (UTX) (SCCO) Downgraded
-
Chardan Trims PT on Esperion (ESPR) to $36 as Negatives Continue Increasing

